Practice Areas & Industries: Jones Day


Antitrust & Competition Law Return to Practice Areas & Industries

Group Profile Lawyers in this Group Offices Locations for this Group

Practice/Industry Group Overview

Having represented clients in some of the most challenging antitrust matters in history, today Jones Day antitrust lawyers handle mergers and acquisitions, government investigations, civil and criminal litigation, and everyday counseling for multinational corporations and innovative small companies around the world.

Our team of more than 150 lawyers located in 25 business centers throughout Asia, Europe, and the Americas has successfully resolved antitrust and competition issues for clients in more than 50 countries and in diverse industries. We have guided clients through their important transactions with strong record of success in hundreds of merger reviews. With our unique combination of trial and antitrust lawyers, we handle multi-jurisdictional investigations and government and private litigation before antitrust enforcement agencies and tribunals worldwide.

Many of Jones Day's antitrust lawyers have served in senior positions in enforcement agencies in the United States, Europe, and Asia and can provide valuable insights into government investigations and decision-making.  Jones Day is the only firm to have had two of its antitrust partners selected, within a period of just four years, to head both U.S. antitrust agencies.  Others have served in various professional organizations throughout the world.  Four of our partners have served as Chair of the influential American Bar Association Section of Antitrust Law.  Several of our lawyers have been recognized in client and peer surveys as ranking among the most prominent and successful competition lawyers in the world.

We are privileged to represent large and small clients in industries ranging from technology and the internet, telecommunications and media, pharmaceuticals and health care, consumer products, and finance to energy, airlines, automobiles, chemicals, manufacturing, transportation, and waste disposal.

Group Presentations
  2013-2014 Life Sciences Webinar Series: Intellectual Property, Regulatory, and Antitrust Issues in Life Sciences M&A and Capital Markets Transactions, November 13, 2013
The New Belgian Competition Act and Recent Developments in Belgian Competition Law, October 17, 2013
Telecoms Conference Series: Challenges Ahead: Resilience or Fragility of Telecoms Through a Period of Economic Stagnation or Decline?, June 17, 2013
Articles Authored by Lawyers at this office:

European Commission’s "Simplified" Merger Control Notification Procedures to Be Effective in 2014
Serge Clerckx,Cecelia Kye, December 17, 2013
The European Commission has adopted a merger simplification package in pursuit of its stated goal of creating a more streamlined and flexible system for its procedures for reviewing concentrations under the EU Merger Regulation No. 139/2004 ("EUMR"), particularly towards alleviating...

Changes Being Effected to Drug Labeling Regime: FDA Releases Proposed Pathway for Generic Safety Updates
Jonathan Berman,Jennifer J. Chheda,Colleen Heisey, December 10, 2013
On November 13, the U.S. Food and Drug Administration ("FDA") published a proposed rule concerning "procedures for application holders of an approved drug or biological product to change the product labeling to reflect certain types of newly acquired information prior to FDA's review...

FTC Closes Investigation of Merger of Office Depot and OfficeMax Office Supply Superstores
, November 22, 2013
The Federal Trade Commission (FTC) has closed its seven-month investigation into the $1.2 billion merger between Office Depot, Inc. and OfficeMax, Inc., the second and third largest "office supply superstores" in the country. The FTC’s decision is of particular interest given the...

FDA Proposes Drug Safety Warning Rule that May Eliminate Preemption Defenses in Some Failure-to-Warn Cases
Jonathan Berman,Colleen Heisey,José A. Isasi, November 19, 2013
In a highly anticipated move, the U.S. Food and Drug Administration ("FDA") has proposed amending its regulations to permit abbreviated new drug application holders (generics) to independently revise product labeling based on newly acquired safety information without prior Agency...

FDA Takes First Step Toward Possible Ban of Partially Hydrogenated Oils
Jonathan Berman,Colleen Heisey, November 19, 2013
On November 7, the Food and Drug Administration ("FDA" or the "Agency") announced that it has tentatively determined that partially hydrogenated oils ("PHOs"), which are the primary dietary source of industrially produced trans fatty acids, are not generally recognized...

FTC Expands Premerger Notification Requirements to Cover Certain Pharmaceutical Patent Licenses
, November 15, 2013
On November 6, 2013, the Federal Trade Commission ("FTC") amended the HSR Act rules to include additional pharmaceutical patent licenses under the premerger notification and waiting period requirements (the "amended rules"). The amended rules specify that an exclusive patent...

Early Warning of Likely Legal Change for Global Distribution Businesses Operating in Australia and New Zealand
Nick Taylor, November 01, 2013
No one finds the law in relation to monopolization or abuse of dominance in Australia and New Zealand (ANZ) to be very satisfactory. Global businesses often have to adapt their practices specifically for their ANZ operations especially in relation to product distribution.

FDA Moves Toward Increased Regulation of Imported Foods: Proposed "FSMA" Regulations Will Impose Heightened Responsibilities on Importers and Will Accredit Third Parties to Audit Compliance
Jonathan Berman,Harold K. Gordon,Colleen Heisey,Kristen E. Scoville, November 01, 2013
In 2013, the U.S. Food and Drug Administration ("FDA") has proposed four major sets of regulations designed to implement the Food Safety Modernization Act ("FSMA"). The first two, released in January, focused on strengthening the regulations governing manufacturing practices and...

U.S. Antitrust Agencies Issue Revised Model Waiver of Confidentiality For Mergers and Non-Merger Civil Investigations
Larissa C. Bergin,J. Bruce McDonald,Ryan C. Thomas,David P. Wales, October 08, 2013
The U.S. antitrust agencies recently issued a revised model waiver of confidentiality for individuals and companies to use in merger and civil non-merger matters that cross international borders. As more companies engage in activities that affect multiple jurisdictions, competition authorities are...

FTC Proposes Study of Patent Assertion Entity Activities, Holdings, and Structure
Gregory L. Lippetz,Geoffrey D. Oliver, October 03, 2013
On September 27, the Federal Trade Commission ("FTC") announced a proposal to use its authority under Section 6(b) of the Federal Trade Commission Act, 15 U.S.C. § 46(b), to issue compulsory process orders requesting detailed information about the makeup and patent assertion...